JP2003502272A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003502272A5 JP2003502272A5 JP2000530520A JP2000530520A JP2003502272A5 JP 2003502272 A5 JP2003502272 A5 JP 2003502272A5 JP 2000530520 A JP2000530520 A JP 2000530520A JP 2000530520 A JP2000530520 A JP 2000530520A JP 2003502272 A5 JP2003502272 A5 JP 2003502272A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- alkoxy
- aryl
- con
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 description 881
- 125000000753 cycloalkyl group Chemical group 0.000 description 776
- 125000003545 alkoxy group Chemical group 0.000 description 331
- 125000001072 heteroaryl group Chemical group 0.000 description 247
- 125000003118 aryl group Chemical group 0.000 description 224
- 125000004104 aryloxy group Chemical group 0.000 description 177
- 229910052739 hydrogen Inorganic materials 0.000 description 149
- 239000001257 hydrogen Substances 0.000 description 149
- 125000005843 halogen group Chemical group 0.000 description 129
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 98
- 125000000623 heterocyclic group Chemical group 0.000 description 65
- 150000002431 hydrogen Chemical class 0.000 description 51
- 150000001875 compounds Chemical class 0.000 description 41
- 229910052717 sulfur Inorganic materials 0.000 description 38
- 125000005336 allyloxy group Chemical group 0.000 description 29
- 125000001309 chloro group Chemical group Cl* 0.000 description 26
- 125000001153 fluoro group Chemical group F* 0.000 description 26
- 125000004432 carbon atom Chemical group C* 0.000 description 23
- -1 methoxyphenyl Chemical group 0.000 description 23
- 229910052760 oxygen Inorganic materials 0.000 description 21
- 150000003839 salts Chemical class 0.000 description 19
- 229910052799 carbon Inorganic materials 0.000 description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
- 150000002148 esters Chemical class 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 17
- 239000012453 solvate Substances 0.000 description 17
- 125000004423 acyloxy group Chemical group 0.000 description 16
- 125000003107 substituted aryl group Chemical group 0.000 description 14
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 12
- 125000002950 monocyclic group Chemical group 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 9
- 229910052727 yttrium Inorganic materials 0.000 description 9
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical compound N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
- 125000001246 bromo group Chemical group Br* 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 150000001204 N-oxides Chemical class 0.000 description 5
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000028389 Nerve injury Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 description 4
- 230000008764 nerve damage Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000004634 feeding behavior Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- DMGOZCOEMMLYBQ-UHFFFAOYSA-N 2-methyl-6-phenyl-4-pyrrolidin-1-yl-5h-pyrrolo[3,2-d]pyrimidine Chemical compound C=12NC(C=3C=CC=CC=3)=CC2=NC(C)=NC=1N1CCCC1 DMGOZCOEMMLYBQ-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 206010027951 Mood swings Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 208000029650 alcohol withdrawal Diseases 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 231100000318 excitotoxic Toxicity 0.000 description 2
- 230000003492 excitotoxic effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000006016 thyroid dysfunction Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KLSNEFPIXYMBHH-UHFFFAOYSA-N 1-(2-methyl-6-phenyl-5h-pyrrolo[3,2-d]pyrimidin-4-yl)pyrrolidin-3-ol Chemical compound C=12NC(C=3C=CC=CC=3)=CC2=NC(C)=NC=1N1CCC(O)C1 KLSNEFPIXYMBHH-UHFFFAOYSA-N 0.000 description 1
- LRDJPMBFLOIIRG-UHFFFAOYSA-N 1-hydroxy-2-(2-methyl-6-phenylpiperidin-4-yl)-2h-thieno[3,2-d]pyrimidine Chemical compound N1C(C)CC(C2N(C=3C=CSC=3C=N2)O)CC1C1=CC=CC=C1 LRDJPMBFLOIIRG-UHFFFAOYSA-N 0.000 description 1
- HQALSHVZJLQPFN-UHFFFAOYSA-N 1-hydroxy-2-(2-methyl-6-phenylpiperidin-4-yl)pyrrolo[3,2-d]pyrimidine Chemical compound N1C(C)CC(C=2N(C3=CC=NC3=CN=2)O)CC1C1=CC=CC=C1 HQALSHVZJLQPFN-UHFFFAOYSA-N 0.000 description 1
- LSELFBQZZQRNQO-UHFFFAOYSA-N 14-methyl-10-phenyl-2,9,13,15-tetrazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),10,12(16),13-tetraene Chemical compound C=1C(C=23)=NC(C)=NC=2N2CCCCC2CN3C=1C1=CC=CC=C1 LSELFBQZZQRNQO-UHFFFAOYSA-N 0.000 description 1
- NRFWKHLSQWNDNN-UHFFFAOYSA-N 2-(2-methyl-6-phenyl-5h-pyrrolo[3,2-d]pyrimidin-4-yl)-1,3-thiazole Chemical compound C=12NC(C=3C=CC=CC=3)=CC2=NC(C)=NC=1C1=NC=CS1 NRFWKHLSQWNDNN-UHFFFAOYSA-N 0.000 description 1
- VQABLVZTEBQHDS-UHFFFAOYSA-N 2-(2-methyl-6-phenylpiperidin-4-yl)furo[3,2-d]pyrimidine Chemical compound N1C(C)CC(C=2N=C3C=COC3=CN=2)CC1C1=CC=CC=C1 VQABLVZTEBQHDS-UHFFFAOYSA-N 0.000 description 1
- GSZYQNUCJIAZJL-UHFFFAOYSA-N 2-(2-methyl-6-phenylpiperidin-4-yl)thieno[3,2-d]pyrimidine Chemical compound N1C(C)CC(C=2N=C3C=CSC3=CN=2)CC1C1=CC=CC=C1 GSZYQNUCJIAZJL-UHFFFAOYSA-N 0.000 description 1
- BVPAWPXJYCYODN-UHFFFAOYSA-N 2-(2-tert-butyl-6-methylpiperidin-4-yl)-1-hydroxy-2h-thieno[3,2-d]pyrimidine Chemical compound C1C(C(C)(C)C)NC(C)CC1C1N(O)C(C=CS2)=C2C=N1 BVPAWPXJYCYODN-UHFFFAOYSA-N 0.000 description 1
- VJTAHVDANNKYPH-UHFFFAOYSA-N 2-(2-tert-butyl-6-methylpiperidin-4-yl)thieno[3,2-d]pyrimidine Chemical compound C1C(C(C)(C)C)NC(C)CC1C1=NC=C(SC=C2)C2=N1 VJTAHVDANNKYPH-UHFFFAOYSA-N 0.000 description 1
- HFIVJEORNLARNN-UHFFFAOYSA-N 2-(4-fluorophenyl)-5-methyl-7-piperidin-1-yl-1h-pyrrolo[3,2-b]pyridine Chemical compound C=12NC(C=3C=CC(F)=CC=3)=CC2=NC(C)=CC=1N1CCCCC1 HFIVJEORNLARNN-UHFFFAOYSA-N 0.000 description 1
- FGISNVXRIOFKCD-UHFFFAOYSA-N 2-(cyclohexen-1-yl)-7-piperidin-1-yl-1h-pyrrolo[3,2-b]pyridine;hydrochloride Chemical compound Cl.C1CCCCN1C1=CC=NC2=C1NC(C=1CCCCC=1)=C2 FGISNVXRIOFKCD-UHFFFAOYSA-N 0.000 description 1
- UNZNOAPSLRPDPE-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)-6-methylpiperidin-4-yl]-1-hydroxy-2h-thieno[3,2-d]pyrimidine Chemical compound N1C(C)CC(C2N(C=3C=CSC=3C=N2)O)CC1C1=CC=C(Cl)C=C1 UNZNOAPSLRPDPE-UHFFFAOYSA-N 0.000 description 1
- MYLPTZDXJPMVMW-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)-6-methylpiperidin-4-yl]thieno[3,2-d]pyrimidine Chemical compound N1C(C)CC(C=2N=C3C=CSC3=CN=2)CC1C1=CC=C(Cl)C=C1 MYLPTZDXJPMVMW-UHFFFAOYSA-N 0.000 description 1
- YRYDJESLVLBPRI-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)-6-methylpiperidin-4-yl]thieno[3,2-d]pyrimidine Chemical compound N1C(C)CC(C=2N=C3C=CSC3=CN=2)CC1C1=CC=C(F)C=C1 YRYDJESLVLBPRI-UHFFFAOYSA-N 0.000 description 1
- VHLAEBPEAQVKAB-UHFFFAOYSA-N 2-cyclohexyl-7-piperidin-1-yl-1h-pyrrolo[3,2-b]pyridine Chemical compound C1CCCCC1C1=CC2=NC=CC(N3CCCCC3)=C2N1 VHLAEBPEAQVKAB-UHFFFAOYSA-N 0.000 description 1
- RNQZOKCAVOJNSG-UHFFFAOYSA-N 2-methyl-4-(2-methylpyrrolidin-1-yl)-6-phenyl-5h-pyrrolo[3,2-d]pyrimidine Chemical compound CC1CCCN1C1=NC(C)=NC2=C1NC(C=1C=CC=CC=1)=C2 RNQZOKCAVOJNSG-UHFFFAOYSA-N 0.000 description 1
- KVZDNBWSPOUUHF-UHFFFAOYSA-N 2-methyl-6-phenyl-4-(4-phenylpiperazin-1-yl)-5h-pyrrolo[3,2-d]pyrimidine Chemical compound C=12NC(C=3C=CC=CC=3)=CC2=NC(C)=NC=1N(CC1)CCN1C1=CC=CC=C1 KVZDNBWSPOUUHF-UHFFFAOYSA-N 0.000 description 1
- WVUPXOVXHJCBCF-UHFFFAOYSA-N 2-methyl-6-phenyl-4-pyridin-3-yl-5h-pyrrolo[3,2-d]pyrimidine Chemical compound C=12NC(C=3C=CC=CC=3)=CC2=NC(C)=NC=1C1=CC=CN=C1 WVUPXOVXHJCBCF-UHFFFAOYSA-N 0.000 description 1
- CSABZLYAAMAGRM-UHFFFAOYSA-N 2-methyl-6-phenyl-4-thiophen-2-yl-5h-pyrrolo[3,2-d]pyrimidine Chemical compound C=12NC(C=3C=CC=CC=3)=CC2=NC(C)=NC=1C1=CC=CS1 CSABZLYAAMAGRM-UHFFFAOYSA-N 0.000 description 1
- BNFLOTVXLMSRMX-UHFFFAOYSA-N 2-phenyl-4-[2-(trifluoromethyl)thiophen-3-yl]piperidine Chemical compound S1C=CC(C2CC(NCC2)C=2C=CC=CC=2)=C1C(F)(F)F BNFLOTVXLMSRMX-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- FGVYRZPTQVFCBR-UHFFFAOYSA-N 3-(7-piperidin-1-yl-1h-pyrrolo[3,2-b]pyridin-2-yl)phenol Chemical compound OC1=CC=CC(C=2NC3=C(N4CCCCC4)C=CN=C3C=2)=C1 FGVYRZPTQVFCBR-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- PDORTDCGJIZCFI-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)-2-methyl-6-phenylthieno[3,2-d]pyrimidine Chemical compound C=1C2=NC(C)=NC(N3CC4=CC=CC=C4CC3)=C2SC=1C1=CC=CC=C1 PDORTDCGJIZCFI-UHFFFAOYSA-N 0.000 description 1
- NWZPSAYBNUDYIN-UHFFFAOYSA-N 4-(3,6-dihydro-2h-pyridin-1-yl)-2-methyl-6-phenylthieno[3,2-d]pyrimidine Chemical compound C=12SC(C=3C=CC=CC=3)=CC2=NC(C)=NC=1N1CCC=CC1 NWZPSAYBNUDYIN-UHFFFAOYSA-N 0.000 description 1
- TZGGZZBAQIYWER-UHFFFAOYSA-N 4-[6-(3,4-difluorophenyl)-2-methyl-5h-pyrrolo[3,2-d]pyrimidin-4-yl]morpholine Chemical compound C=12NC(C=3C=C(F)C(F)=CC=3)=CC2=NC(C)=NC=1N1CCOCC1 TZGGZZBAQIYWER-UHFFFAOYSA-N 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- JIJBNODYTQRFQR-UHFFFAOYSA-N 6-(4-fluorophenyl)-2-methyl-4-(2-methylpiperidin-1-yl)-5h-pyrrolo[3,2-d]pyrimidine Chemical compound CC1CCCCN1C1=NC(C)=NC2=C1NC(C=1C=CC(F)=CC=1)=C2 JIJBNODYTQRFQR-UHFFFAOYSA-N 0.000 description 1
- SZZDYFWEHMPCAS-UHFFFAOYSA-N 7-piperidin-1-yl-2-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine Chemical compound C1CCCCN1C1=CC=NC2=C1NC(C=1N=CC=CC=1)=C2 SZZDYFWEHMPCAS-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- ZJSHGKFUEPNFHP-UHFFFAOYSA-N C(C)C1=NC(=C2C(N1)=CC(=N2)C2=CC=CC=C2)N2CC1=CC=CC=C1CC2 Chemical compound C(C)C1=NC(=C2C(N1)=CC(=N2)C2=CC=CC=C2)N2CC1=CC=CC=C1CC2 ZJSHGKFUEPNFHP-UHFFFAOYSA-N 0.000 description 1
- AREJQYKTNHEJRM-UHFFFAOYSA-N C1(=CC=CC=C1)C1CC(CCN1)C1=C2C(NC(=N1)NCCC)=CC=N2 Chemical compound C1(=CC=CC=C1)C1CC(CCN1)C1=C2C(NC(=N1)NCCC)=CC=N2 AREJQYKTNHEJRM-UHFFFAOYSA-N 0.000 description 1
- IULADUGXHYYHPM-UHFFFAOYSA-N C12(CC3CC(CC(C1)C3)C2)C2CC(CC(N2)C)C2=NC=C3C(N2)=CC=N3 Chemical compound C12(CC3CC(CC(C1)C3)C2)C2CC(CC(N2)C)C2=NC=C3C(N2)=CC=N3 IULADUGXHYYHPM-UHFFFAOYSA-N 0.000 description 1
- DYHKIZKGIGJEDE-UHFFFAOYSA-N C1=C2NC(C)=NC(N3C4CCC3CCC4)=C2N=C1C1=CC=CC=C1 Chemical compound C1=C2NC(C)=NC(N3C4CCC3CCC4)=C2N=C1C1=CC=CC=C1 DYHKIZKGIGJEDE-UHFFFAOYSA-N 0.000 description 1
- LJYNJEIJQYGDMT-UHFFFAOYSA-N C1CC(CC(N1)c1ccccc1)Nc1ncc2nccc2[nH]1 Chemical compound C1CC(CC(N1)c1ccccc1)Nc1ncc2nccc2[nH]1 LJYNJEIJQYGDMT-UHFFFAOYSA-N 0.000 description 1
- OXTKALMGVPAARX-UHFFFAOYSA-N C1CC1C1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1 Chemical compound C1CC1C1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1 OXTKALMGVPAARX-UHFFFAOYSA-N 0.000 description 1
- JJLRHWKCKULJLT-UHFFFAOYSA-N C1CN(CCN1C1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1)c1ccccc1 Chemical compound C1CN(CCN1C1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1)c1ccccc1 JJLRHWKCKULJLT-UHFFFAOYSA-N 0.000 description 1
- UZXVPKWNXQWRLJ-UHFFFAOYSA-N C1CNC(C)CC1C(N1)=NC=C2C1=CC(C=1C=C(N)C=CC=1)=N2 Chemical compound C1CNC(C)CC1C(N1)=NC=C2C1=CC(C=1C=C(N)C=CC=1)=N2 UZXVPKWNXQWRLJ-UHFFFAOYSA-N 0.000 description 1
- MAYRGCAQXKIOEJ-UHFFFAOYSA-N C1CNC(C)CC1C(N1)=NC=C2C1=CC(C=1C=CC(N)=CC=1)=N2 Chemical compound C1CNC(C)CC1C(N1)=NC=C2C1=CC(C=1C=CC(N)=CC=1)=N2 MAYRGCAQXKIOEJ-UHFFFAOYSA-N 0.000 description 1
- PYQPLUULKKMMBG-UHFFFAOYSA-N CC(C)C1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1 Chemical compound CC(C)C1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1 PYQPLUULKKMMBG-UHFFFAOYSA-N 0.000 description 1
- VELBIJQHOXXDHB-UHFFFAOYSA-N CC(C)CC1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1 Chemical compound CC(C)CC1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1 VELBIJQHOXXDHB-UHFFFAOYSA-N 0.000 description 1
- JQWKQFINJKXFBA-UHFFFAOYSA-N CC1=NC(=C2C(N1)=CC(=N2)C2=CC=CC=C2)N2CCC=CC2 Chemical compound CC1=NC(=C2C(N1)=CC(=N2)C2=CC=CC=C2)N2CCC=CC2 JQWKQFINJKXFBA-UHFFFAOYSA-N 0.000 description 1
- HEKUQHJRYKYKHO-UHFFFAOYSA-N CC1CC(CC(C)N1)c1ncc2ncc(-c3ccc(F)cc3)c2[nH]1 Chemical compound CC1CC(CC(C)N1)c1ncc2ncc(-c3ccc(F)cc3)c2[nH]1 HEKUQHJRYKYKHO-UHFFFAOYSA-N 0.000 description 1
- VJCBUYUQMIBJAO-UHFFFAOYSA-N CC1CC(CC(CCc2ccccc2)N1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(CCc2ccccc2)N1)c1ncc2nccc2[nH]1 VJCBUYUQMIBJAO-UHFFFAOYSA-N 0.000 description 1
- FZIQSIBPOOEOHF-UHFFFAOYSA-N CC1CC(CC(Cc2ccc(F)cc2)N1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(Cc2ccc(F)cc2)N1)c1ncc2nccc2[nH]1 FZIQSIBPOOEOHF-UHFFFAOYSA-N 0.000 description 1
- SMYMWOJVKSYQAT-UHFFFAOYSA-N CC1CC(CC(N1)C(C)(C)C)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)C(C)(C)C)c1ncc2nccc2[nH]1 SMYMWOJVKSYQAT-UHFFFAOYSA-N 0.000 description 1
- NTKFUIVUDYAFFC-UHFFFAOYSA-N CC1CC(CC(N1)C1=C(C)CCC1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)C1=C(C)CCC1)c1ncc2nccc2[nH]1 NTKFUIVUDYAFFC-UHFFFAOYSA-N 0.000 description 1
- FLGNHOHKBCJJQT-UHFFFAOYSA-N CC1CC(CC(N1)C2=CC=C(C=C2)Cl)C3=NC=C4C(=N3)C=CO4 Chemical compound CC1CC(CC(N1)C2=CC=C(C=C2)Cl)C3=NC=C4C(=N3)C=CO4 FLGNHOHKBCJJQT-UHFFFAOYSA-N 0.000 description 1
- XXNWKVBSHGWDBE-UHFFFAOYSA-N CC1CC(CC(N1)c1c(F)cccc1F)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)c1c(F)cccc1F)c1ncc2nccc2[nH]1 XXNWKVBSHGWDBE-UHFFFAOYSA-N 0.000 description 1
- CUWROPSTRNSTMY-UHFFFAOYSA-N CC1CC(CC(N1)c1cc(F)cc(F)c1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)c1cc(F)cc(F)c1)c1ncc2nccc2[nH]1 CUWROPSTRNSTMY-UHFFFAOYSA-N 0.000 description 1
- WJFQKXRCHWORFM-UHFFFAOYSA-N CC1CC(CC(N1)c1cc(F)ccc1F)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)c1cc(F)ccc1F)c1ncc2nccc2[nH]1 WJFQKXRCHWORFM-UHFFFAOYSA-N 0.000 description 1
- LBZMDNWEGSMCFM-UHFFFAOYSA-N CC1CC(CC(N1)c1ccc(C)c(C)c1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)c1ccc(C)c(C)c1)c1ncc2nccc2[nH]1 LBZMDNWEGSMCFM-UHFFFAOYSA-N 0.000 description 1
- WREYEVOZVIERLR-UHFFFAOYSA-N CC1CC(CC(N1)c1ccc(C)cc1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)c1ccc(C)cc1)c1ncc2nccc2[nH]1 WREYEVOZVIERLR-UHFFFAOYSA-N 0.000 description 1
- WCYJORQWHSDHBR-UHFFFAOYSA-N CC1CC(CC(N1)c1ccc(Cl)c(Cl)c1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)c1ccc(Cl)c(Cl)c1)c1ncc2nccc2[nH]1 WCYJORQWHSDHBR-UHFFFAOYSA-N 0.000 description 1
- VBJRYQZUCOKMHE-UHFFFAOYSA-N CC1CC(CC(N1)c1ccc(Cl)cc1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)c1ccc(Cl)cc1)c1ncc2nccc2[nH]1 VBJRYQZUCOKMHE-UHFFFAOYSA-N 0.000 description 1
- DWSUBFQFDPCNSA-UHFFFAOYSA-N CC1CC(CC(N1)c1ccc(F)cc1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)c1ccc(F)cc1)c1ncc2nccc2[nH]1 DWSUBFQFDPCNSA-UHFFFAOYSA-N 0.000 description 1
- OANKKENGKFVDIV-UHFFFAOYSA-N CC1CC(CC(N1)c1ccc(cc1)-c1ccccc1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)c1ccc(cc1)-c1ccccc1)c1ncc2nccc2[nH]1 OANKKENGKFVDIV-UHFFFAOYSA-N 0.000 description 1
- NXEWWDOTNDISSE-UHFFFAOYSA-N CC1CC(CC(N1)c1ccc-2c(Cc3ccccc-23)c1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)c1ccc-2c(Cc3ccccc-23)c1)c1ncc2nccc2[nH]1 NXEWWDOTNDISSE-UHFFFAOYSA-N 0.000 description 1
- OAAHRKGZWXHAOM-UHFFFAOYSA-N CC1CC(CC(N1)c1ccc2CCCc2c1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)c1ccc2CCCc2c1)c1ncc2nccc2[nH]1 OAAHRKGZWXHAOM-UHFFFAOYSA-N 0.000 description 1
- APOKDLVUUOYZIO-UHFFFAOYSA-N CC1CC(CC(N1)c1ccc2ccccc2c1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)c1ccc2ccccc2c1)c1ncc2nccc2[nH]1 APOKDLVUUOYZIO-UHFFFAOYSA-N 0.000 description 1
- NXKDZKLZZCTKEN-UHFFFAOYSA-N CC1CC(CC(N1)c1cccc(Cl)c1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)c1cccc(Cl)c1)c1ncc2nccc2[nH]1 NXKDZKLZZCTKEN-UHFFFAOYSA-N 0.000 description 1
- KPYSDBCHGMBEOL-UHFFFAOYSA-N CC1CC(CC(N1)c1ccccc1)c1ncc2ncc(Br)c2[nH]1 Chemical compound CC1CC(CC(N1)c1ccccc1)c1ncc2ncc(Br)c2[nH]1 KPYSDBCHGMBEOL-UHFFFAOYSA-N 0.000 description 1
- NMLQRNATQNHJEB-UHFFFAOYSA-N CC1CC(CC(N1)c1ccccc1F)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)c1ccccc1F)c1ncc2nccc2[nH]1 NMLQRNATQNHJEB-UHFFFAOYSA-N 0.000 description 1
- BXDKSLZIWGWFGY-UHFFFAOYSA-N CC1CC(CC(N1)c1cnn(c1C)-c1ccccc1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CC(N1)c1cnn(c1C)-c1ccccc1)c1ncc2nccc2[nH]1 BXDKSLZIWGWFGY-UHFFFAOYSA-N 0.000 description 1
- ODIKWQFQBSTFOL-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(CS(=O)(=O)c3ccc(Cl)cc3)cc2[nH]1 Chemical compound CC1CC(CCN1)c1ncc2nc(CS(=O)(=O)c3ccc(Cl)cc3)cc2[nH]1 ODIKWQFQBSTFOL-UHFFFAOYSA-N 0.000 description 1
- MOSWJASDIAXSGJ-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1cc(C)sc1C Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1cc(C)sc1C MOSWJASDIAXSGJ-UHFFFAOYSA-N 0.000 description 1
- MONMQNKXSLFXQX-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1cc(F)c(F)c(F)c1 Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1cc(F)c(F)c(F)c1 MONMQNKXSLFXQX-UHFFFAOYSA-N 0.000 description 1
- XONWLXZQAAGYHS-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1cc2ccccc2o1 Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1cc2ccccc2o1 XONWLXZQAAGYHS-UHFFFAOYSA-N 0.000 description 1
- OFVJIESDXWQLON-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(O)cc1 Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(O)cc1 OFVJIESDXWQLON-UHFFFAOYSA-N 0.000 description 1
- MOBBUDZQSJZSPG-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(OC(F)(F)F)cc1 Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(OC(F)(F)F)cc1 MOBBUDZQSJZSPG-UHFFFAOYSA-N 0.000 description 1
- VFZNPDVXJNCAHP-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(SC(F)(F)F)cc1 Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(SC(F)(F)F)cc1 VFZNPDVXJNCAHP-UHFFFAOYSA-N 0.000 description 1
- NYNSDKPIUKKJEL-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(cc1)C(C)=O Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(cc1)C(C)=O NYNSDKPIUKKJEL-UHFFFAOYSA-N 0.000 description 1
- OTMAVUOYKGINHK-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(cc1)C(F)(F)F Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(cc1)C(F)(F)F OTMAVUOYKGINHK-UHFFFAOYSA-N 0.000 description 1
- PUEFELNCHPWLBM-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(cc1)C1CC(CC(C)N1)c1ncc2nccc2[nH]1 Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(cc1)C1CC(CC(C)N1)c1ncc2nccc2[nH]1 PUEFELNCHPWLBM-UHFFFAOYSA-N 0.000 description 1
- QVWJNZFAUUFHHA-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(cc1)S(C)(=O)=O Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(cc1)S(C)(=O)=O QVWJNZFAUUFHHA-UHFFFAOYSA-N 0.000 description 1
- HESQVCXCJPRTKZ-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(o1)-c1ccc(F)c(Cl)c1 Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc(o1)-c1ccc(F)c(Cl)c1 HESQVCXCJPRTKZ-UHFFFAOYSA-N 0.000 description 1
- XTKSYCHNDZONBH-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc2OCCc2c1 Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccc2OCCc2c1 XTKSYCHNDZONBH-UHFFFAOYSA-N 0.000 description 1
- WWZRJXVFEHAFBN-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1cccc(c1)C(F)(F)F Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1cccc(c1)C(F)(F)F WWZRJXVFEHAFBN-UHFFFAOYSA-N 0.000 description 1
- LZXHSVZICNCOLH-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccccn1 Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccccn1 LZXHSVZICNCOLH-UHFFFAOYSA-N 0.000 description 1
- PDRDVXRSIIQTDY-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1cccs1 Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1cccs1 PDRDVXRSIIQTDY-UHFFFAOYSA-N 0.000 description 1
- WLRBLBJZMBZUJD-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccn(c1)S(=O)(=O)c1ccccc1 Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1ccn(c1)S(=O)(=O)c1ccccc1 WLRBLBJZMBZUJD-UHFFFAOYSA-N 0.000 description 1
- CYCBDGVNBNHFLI-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1cnccn1 Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1cnccn1 CYCBDGVNBNHFLI-UHFFFAOYSA-N 0.000 description 1
- YBPOMOBOCTUKSN-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1sc(C)nc1C Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1sc(C)nc1C YBPOMOBOCTUKSN-UHFFFAOYSA-N 0.000 description 1
- GTCOYSYIPSEJDQ-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1sc2ccc(C)cc2c1C Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1sc2ccc(C)cc2c1C GTCOYSYIPSEJDQ-UHFFFAOYSA-N 0.000 description 1
- SCCSIUDHSQVEPW-UHFFFAOYSA-N CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1sc2ccccc2c1C Chemical compound CC1CC(CCN1)c1ncc2nc(cc2[nH]1)-c1sc2ccccc2c1C SCCSIUDHSQVEPW-UHFFFAOYSA-N 0.000 description 1
- SESOLRBHRYFSGW-UHFFFAOYSA-N CC1NC(C(C(C1)C1=NC=C2C(N1)=CC=N2)C)C2=CC=CC=C2.CC=2NC=1C(=C(N2)N2CC(CCC2)CO)N=C(C1)C1=CC=CC=C1 Chemical compound CC1NC(C(C(C1)C1=NC=C2C(N1)=CC=N2)C)C2=CC=CC=C2.CC=2NC=1C(=C(N2)N2CC(CCC2)CO)N=C(C1)C1=CC=CC=C1 SESOLRBHRYFSGW-UHFFFAOYSA-N 0.000 description 1
- AZVPBYKCBJVWPQ-UHFFFAOYSA-N CC1NC(CC(C1)C1=NC=C2C(N1)=C(C=N2)C)C2=CC=CC=C2 Chemical compound CC1NC(CC(C1)C1=NC=C2C(N1)=C(C=N2)C)C2=CC=CC=C2 AZVPBYKCBJVWPQ-UHFFFAOYSA-N 0.000 description 1
- SMMHVSFFBDHGQE-UHFFFAOYSA-N CC1NC(CC(C1)C1=NC=C2C(N1)=C(C=N2)CC2=CC=CC=C2)C Chemical compound CC1NC(CC(C1)C1=NC=C2C(N1)=C(C=N2)CC2=CC=CC=C2)C SMMHVSFFBDHGQE-UHFFFAOYSA-N 0.000 description 1
- MHWAKQXYDINJQC-UHFFFAOYSA-N CC1NC(CC(C1)C1=NC=C2C(N1)=C(C=N2)OC2=CC=CC=C2)C Chemical compound CC1NC(CC(C1)C1=NC=C2C(N1)=C(C=N2)OC2=CC=CC=C2)C MHWAKQXYDINJQC-UHFFFAOYSA-N 0.000 description 1
- YMEGFYZILXDRLZ-UHFFFAOYSA-N CC1NCCC(C1)C1=NC=C2C(N1)=C(C(=N2)C2=CC(=CC=C2)OC)C Chemical compound CC1NCCC(C1)C1=NC=C2C(N1)=C(C(=N2)C2=CC(=CC=C2)OC)C YMEGFYZILXDRLZ-UHFFFAOYSA-N 0.000 description 1
- LIEDOSQPIYSYBR-UHFFFAOYSA-N CC1NCCC(C1)C1=NC=C2C(N1)=C(C(=N2)C2=CC=C(C=C2)O)C Chemical compound CC1NCCC(C1)C1=NC=C2C(N1)=C(C(=N2)C2=CC=C(C=C2)O)C LIEDOSQPIYSYBR-UHFFFAOYSA-N 0.000 description 1
- CPMSQKSISCAVGY-UHFFFAOYSA-N CC1NCCC(C1)C1=NC=C2C(N1)=C(C(=N2)C2=CC=C(C=C2)OC)C Chemical compound CC1NCCC(C1)C1=NC=C2C(N1)=C(C(=N2)C2=CC=C(C=C2)OC)C CPMSQKSISCAVGY-UHFFFAOYSA-N 0.000 description 1
- JOWDGIRBTWWZMR-UHFFFAOYSA-N CC1NCCC(C1)C1=NC=C2C(N1)=CC(=N2)C2=CC(=C(C(=C2)Cl)Cl)Cl Chemical compound CC1NCCC(C1)C1=NC=C2C(N1)=CC(=N2)C2=CC(=C(C(=C2)Cl)Cl)Cl JOWDGIRBTWWZMR-UHFFFAOYSA-N 0.000 description 1
- MLZACVDXGPNMAZ-UHFFFAOYSA-N CC1NCCC(C1)C1=NC=C2C(N1)=CC(=N2)C2=CC=1CCCCC1C=C2 Chemical compound CC1NCCC(C1)C1=NC=C2C(N1)=CC(=N2)C2=CC=1CCCCC1C=C2 MLZACVDXGPNMAZ-UHFFFAOYSA-N 0.000 description 1
- PBUHLVXQCDRUBW-UHFFFAOYSA-N CC=1NC=2C(=C(N1)N1C(CNCC1)S(=O)(=O)C1=CC=CC=C1)N=C(C2)C2=CC=CC=C2 Chemical compound CC=1NC=2C(=C(N1)N1C(CNCC1)S(=O)(=O)C1=CC=CC=C1)N=C(C2)C2=CC=CC=C2 PBUHLVXQCDRUBW-UHFFFAOYSA-N 0.000 description 1
- JCHYJPVVNWEKES-UHFFFAOYSA-N CC=1NC=2C(=C(N=1)N1CCC3(OCCO3)CC1)N=C(C=2)C1=CC=CC=C1 Chemical compound CC=1NC=2C(=C(N=1)N1CCC3(OCCO3)CC1)N=C(C=2)C1=CC=CC=C1 JCHYJPVVNWEKES-UHFFFAOYSA-N 0.000 description 1
- GJAPIAWXAOINJE-UHFFFAOYSA-N CCC1CC(CC(N1)C2=CC=C(C=C2)Cl)C3=NC=C4C(=N3)C=CO4 Chemical compound CCC1CC(CC(N1)C2=CC=C(C=C2)Cl)C3=NC=C4C(=N3)C=CO4 GJAPIAWXAOINJE-UHFFFAOYSA-N 0.000 description 1
- DEOGHUOTWLUMAR-UHFFFAOYSA-N CCC1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1 Chemical compound CCC1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1 DEOGHUOTWLUMAR-UHFFFAOYSA-N 0.000 description 1
- VMCGFBVHDLNEQS-UHFFFAOYSA-N CCCCC1CC(CC(C)N1)c1ncc2nccc2[nH]1 Chemical compound CCCCC1CC(CC(C)N1)c1ncc2nccc2[nH]1 VMCGFBVHDLNEQS-UHFFFAOYSA-N 0.000 description 1
- XIKDOMCVHCIACP-UHFFFAOYSA-N CCCc1cnc2cnc([nH]c12)C1CC(C)NC(C)C1 Chemical compound CCCc1cnc2cnc([nH]c12)C1CC(C)NC(C)C1 XIKDOMCVHCIACP-UHFFFAOYSA-N 0.000 description 1
- HTOZHZBOCHGWSA-UHFFFAOYSA-N CCCc1nc(C2CCNC(C2)c2ccccc2)c2nccc2[nH]1 Chemical compound CCCc1nc(C2CCNC(C2)c2ccccc2)c2nccc2[nH]1 HTOZHZBOCHGWSA-UHFFFAOYSA-N 0.000 description 1
- BXVHOMQIPFLWPG-UHFFFAOYSA-N CCc1cnc2cnc([nH]c12)C1CC(C)NC(C1)c1ccccc1 Chemical compound CCc1cnc2cnc([nH]c12)C1CC(C)NC(C1)c1ccccc1 BXVHOMQIPFLWPG-UHFFFAOYSA-N 0.000 description 1
- OAXVPUPRAFFRLG-UHFFFAOYSA-N COC1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1 Chemical compound COC1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1 OAXVPUPRAFFRLG-UHFFFAOYSA-N 0.000 description 1
- HPRJONGSZNSUQI-UHFFFAOYSA-N COc1cc(cc(OC)c1OC)-c1cc2[nH]c(ncc2n1)C1CCNC(C)C1 Chemical compound COc1cc(cc(OC)c1OC)-c1cc2[nH]c(ncc2n1)C1CCNC(C)C1 HPRJONGSZNSUQI-UHFFFAOYSA-N 0.000 description 1
- APFZPLNMIZERCE-UHFFFAOYSA-N COc1ccc(Cc2cc3[nH]c(ncc3n2)C2CCNC(C)C2)cc1 Chemical compound COc1ccc(Cc2cc3[nH]c(ncc3n2)C2CCNC(C)C2)cc1 APFZPLNMIZERCE-UHFFFAOYSA-N 0.000 description 1
- WWZCPMHLUCONKY-UHFFFAOYSA-N COc1ccc(cc1)-c1cc2[nH]c(ncc2n1)C1CCNC(C)C1 Chemical compound COc1ccc(cc1)-c1cc2[nH]c(ncc2n1)C1CCNC(C)C1 WWZCPMHLUCONKY-UHFFFAOYSA-N 0.000 description 1
- YNDHVRWHXFEHAC-UHFFFAOYSA-N COc1ccc(cc1)-c1cnc2cnc([nH]c12)C1CC(C)NC(C)C1 Chemical compound COc1ccc(cc1)-c1cnc2cnc([nH]c12)C1CC(C)NC(C)C1 YNDHVRWHXFEHAC-UHFFFAOYSA-N 0.000 description 1
- AHONREMVGOGIHH-UHFFFAOYSA-N COc1ccc(cc1F)-c1cc2[nH]c(ncc2n1)C1CCNC(C)C1 Chemical compound COc1ccc(cc1F)-c1cc2[nH]c(ncc2n1)C1CCNC(C)C1 AHONREMVGOGIHH-UHFFFAOYSA-N 0.000 description 1
- MDBPCVFPBOQMEH-UHFFFAOYSA-N COc1ccc(cc1OC)-c1cc2[nH]c(ncc2n1)C1CCNC(C)C1 Chemical compound COc1ccc(cc1OC)-c1cc2[nH]c(ncc2n1)C1CCNC(C)C1 MDBPCVFPBOQMEH-UHFFFAOYSA-N 0.000 description 1
- CFHDVAINYORGQM-UHFFFAOYSA-N COc1cccc2cc(oc12)-c1cc2[nH]c(ncc2n1)C1CCNC(C)C1 Chemical compound COc1cccc2cc(oc12)-c1cc2[nH]c(ncc2n1)C1CCNC(C)C1 CFHDVAINYORGQM-UHFFFAOYSA-N 0.000 description 1
- JFBJSMZMZCMOIQ-UHFFFAOYSA-N CSC1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1 Chemical compound CSC1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1 JFBJSMZMZCMOIQ-UHFFFAOYSA-N 0.000 description 1
- NVLHTSRJGWGBMO-KBPBESRZSA-N C[C@@H]1CN(C[C@H](C1)C)C1=C2C(NC(=N1)C)=CC(=N2)C1=CC=CC=C1 Chemical compound C[C@@H]1CN(C[C@H](C1)C)C1=C2C(NC(=N1)C)=CC(=N2)C1=CC=CC=C1 NVLHTSRJGWGBMO-KBPBESRZSA-N 0.000 description 1
- ROBDNBFFFBDKBR-BETUJISGSA-N C[C@H]1N([C@H](CCC1)C)C1=C2C(NC(=N1)C)=CC(=N2)C2=CC=C(C=C2)F Chemical compound C[C@H]1N([C@H](CCC1)C)C1=C2C(NC(=N1)C)=CC(=N2)C2=CC=C(C=C2)F ROBDNBFFFBDKBR-BETUJISGSA-N 0.000 description 1
- RBOQOUPVUUFFMR-UHFFFAOYSA-N Cc1nc(N2CCC(O)(CC2)c2cccc(c2)C(F)(F)F)c2nc(cc2[nH]1)-c1ccccc1 Chemical compound Cc1nc(N2CCC(O)(CC2)c2cccc(c2)C(F)(F)F)c2nc(cc2[nH]1)-c1ccccc1 RBOQOUPVUUFFMR-UHFFFAOYSA-N 0.000 description 1
- LRCVWGYIEZYNDH-UHFFFAOYSA-N Cc1nc(N2CCC(O)CC2)c2nc(cc2[nH]1)-c1ccccc1 Chemical compound Cc1nc(N2CCC(O)CC2)c2nc(cc2[nH]1)-c1ccccc1 LRCVWGYIEZYNDH-UHFFFAOYSA-N 0.000 description 1
- QHJOIOXEPYNFIZ-UHFFFAOYSA-N Cc1nc(N2CCCC(O)C2)c2nc(cc2[nH]1)-c1ccccc1 Chemical compound Cc1nc(N2CCCC(O)C2)c2nc(cc2[nH]1)-c1ccccc1 QHJOIOXEPYNFIZ-UHFFFAOYSA-N 0.000 description 1
- LLJXLTASNLBFIG-UHFFFAOYSA-N Cc1nc(N2CCCCC2=O)c2nc(cc2[nH]1)-c1ccccc1 Chemical compound Cc1nc(N2CCCCC2=O)c2nc(cc2[nH]1)-c1ccccc1 LLJXLTASNLBFIG-UHFFFAOYSA-N 0.000 description 1
- HINAKTVDVVKJJY-AWEZNQCLSA-N Cc1nc(N2CCC[C@H]2CO)c2nc(cc2[nH]1)-c1ccccc1 Chemical compound Cc1nc(N2CCC[C@H]2CO)c2nc(cc2[nH]1)-c1ccccc1 HINAKTVDVVKJJY-AWEZNQCLSA-N 0.000 description 1
- DILHVXUCRGGSFN-UHFFFAOYSA-N Cc1nc(N2CCN(CC2)C(=O)c2ccco2)c2nc(cc2[nH]1)-c1ccccc1 Chemical compound Cc1nc(N2CCN(CC2)C(=O)c2ccco2)c2nc(cc2[nH]1)-c1ccccc1 DILHVXUCRGGSFN-UHFFFAOYSA-N 0.000 description 1
- BEGDAFKKAPQFTM-UHFFFAOYSA-N Cc1nc(N2CCN(CC2)S(C)(=O)=O)c2nc(cc2[nH]1)-c1ccccc1 Chemical compound Cc1nc(N2CCN(CC2)S(C)(=O)=O)c2nc(cc2[nH]1)-c1ccccc1 BEGDAFKKAPQFTM-UHFFFAOYSA-N 0.000 description 1
- JBHSRZYUVUIDLU-UHFFFAOYSA-N ClC1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1 Chemical compound ClC1CC(CC(N1)c1ccccc1)c1ncc2nccc2[nH]1 JBHSRZYUVUIDLU-UHFFFAOYSA-N 0.000 description 1
- VFSDNPZDVATOIW-UHFFFAOYSA-N ClC=1C=C(C=CC1Cl)C1CC(CC(N1)C)C1=NC=C2C(N1)=C(C=N2)C Chemical compound ClC=1C=C(C=CC1Cl)C1CC(CC(N1)C)C1=NC=C2C(N1)=C(C=N2)C VFSDNPZDVATOIW-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- KOZLDVPYLMHVMS-UHFFFAOYSA-N FC(F)(F)c1nc(C2CCNC(C2)c2ccccc2)c2nccc2[nH]1 Chemical compound FC(F)(F)c1nc(C2CCNC(C2)c2ccccc2)c2nccc2[nH]1 KOZLDVPYLMHVMS-UHFFFAOYSA-N 0.000 description 1
- MIHZERXIRZOLRG-UHFFFAOYSA-N FC1=C(C=CC(=C1)C1=NC=2C(NC(=NC2)C2CC(NCC2)C)=C1)O Chemical compound FC1=C(C=CC(=C1)C1=NC=2C(NC(=NC2)C2CC(NCC2)C)=C1)O MIHZERXIRZOLRG-UHFFFAOYSA-N 0.000 description 1
- LIPJYVPJBDXGTM-UHFFFAOYSA-N FC1=CC=C(C=C1)C1CC(CC(N1)C)C1=NC=C2C(N1)=C(C=N2)C Chemical compound FC1=CC=C(C=C1)C1CC(CC(N1)C)C1=NC=C2C(N1)=C(C=N2)C LIPJYVPJBDXGTM-UHFFFAOYSA-N 0.000 description 1
- DKWSXPNVQBGUQK-UHFFFAOYSA-N FC=1C(=NC=2C1NC(=NC2)C)N2CCCCC2 Chemical compound FC=1C(=NC=2C1NC(=NC2)C)N2CCCCC2 DKWSXPNVQBGUQK-UHFFFAOYSA-N 0.000 description 1
- ZGIUBGBRSRRPJT-UHFFFAOYSA-N FC=1C=C(C=C(C1)F)C1CC(CC(N1)C)C1=NC=C2C(N1)=C(C=N2)C Chemical compound FC=1C=C(C=C(C1)F)C1CC(CC(N1)C)C1=NC=C2C(N1)=C(C=N2)C ZGIUBGBRSRRPJT-UHFFFAOYSA-N 0.000 description 1
- OVXHXJHTMQDHFY-UHFFFAOYSA-N FC=1C=C(C=CC1F)C1CC(CC(N1)C)C1=NC=C2C(N1)=C(C=N2)C Chemical compound FC=1C=C(C=CC1F)C1CC(CC(N1)C)C1=NC=C2C(N1)=C(C=N2)C OVXHXJHTMQDHFY-UHFFFAOYSA-N 0.000 description 1
- OODRCFPQHVRQNB-UHFFFAOYSA-N Fc1ccc(cc1)C1CC(CC(N1)C1CC1)c1ncc2nccc2[nH]1 Chemical compound Fc1ccc(cc1)C1CC(CC(N1)C1CC1)c1ncc2nccc2[nH]1 OODRCFPQHVRQNB-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- GFUINYQBPVXMJD-UHFFFAOYSA-N N1(CCC1)C1=C2C(NC(=N1)C)=CC(=N2)C2=CC=CC=C2 Chemical compound N1(CCC1)C1=C2C(NC(=N1)C)=CC(=N2)C2=CC=CC=C2 GFUINYQBPVXMJD-UHFFFAOYSA-N 0.000 description 1
- WNPPGWSXCFWWRL-UHFFFAOYSA-N N1(CCC2=CC=CC=C12)C1=C2C(NC(=N1)C)=CC(=N2)C2=CC=CC=C2 Chemical compound N1(CCC2=CC=CC=C12)C1=C2C(NC(=N1)C)=CC(=N2)C2=CC=CC=C2 WNPPGWSXCFWWRL-UHFFFAOYSA-N 0.000 description 1
- NSHUQEMKLRYEBF-UHFFFAOYSA-N N1C(=NC=C2C1=CC=N2)NO Chemical compound N1C(=NC=C2C1=CC=N2)NO NSHUQEMKLRYEBF-UHFFFAOYSA-N 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XSCRHYVGTZZTGN-UHFFFAOYSA-N chembl137058 Chemical compound CC1CCCCN1C1=C2N=C(C=3C=CC=CC=3)C=C2N=C(C)N1 XSCRHYVGTZZTGN-UHFFFAOYSA-N 0.000 description 1
- XVPHXXUIVDUAMH-UHFFFAOYSA-N chembl334373 Chemical compound CCC1CCCCN1C1=C2N=C(C=3C=CC=CC=3)C=C2N=C(C)N1 XVPHXXUIVDUAMH-UHFFFAOYSA-N 0.000 description 1
- SSDZDEJUZLMUDX-UHFFFAOYSA-N chembl342918 Chemical compound C1CN(C(=O)C)CCN1C1=C2N=C(C=3C=CC=CC=3)C=C2N=C(C)N1 SSDZDEJUZLMUDX-UHFFFAOYSA-N 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- JUQAECQBUNODQP-UHFFFAOYSA-N furo[3,2-d]pyrimidine Chemical compound C1=NC=C2OC=CC2=N1 JUQAECQBUNODQP-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- DRPLTFIHCZOFME-UHFFFAOYSA-N n,n-dimethyl-1-[1-(2-methyl-6-phenyl-5h-pyrrolo[3,2-d]pyrimidin-4-yl)piperidin-2-yl]methanamine Chemical compound CN(C)CC1CCCCN1C1=NC(C)=NC2=C1NC(C=1C=CC=CC=1)=C2 DRPLTFIHCZOFME-UHFFFAOYSA-N 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7392798P | 1998-02-06 | 1998-02-06 | |
| US7398198P | 1998-02-06 | 1998-02-06 | |
| US60/073,981 | 1998-02-06 | ||
| US60/073,927 | 1998-02-06 | ||
| US9357798P | 1998-07-20 | 1998-07-20 | |
| US9348298P | 1998-07-20 | 1998-07-20 | |
| US60/093,577 | 1998-07-20 | ||
| US60/093,482 | 1998-07-20 | ||
| US09/246,775 | 1999-02-04 | ||
| US09/246,775 US6187777B1 (en) | 1998-02-06 | 1999-02-04 | Compounds and methods which modulate feeding behavior and related diseases |
| PCT/US1999/002500 WO1999040091A1 (en) | 1998-02-06 | 1999-02-05 | Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003502272A JP2003502272A (ja) | 2003-01-21 |
| JP2003502272A5 true JP2003502272A5 (https=) | 2006-01-19 |
Family
ID=27535987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000530520A Withdrawn JP2003502272A (ja) | 1998-02-06 | 1999-02-05 | 神経ペプチドｙ受容体拮抗薬としての二環式ピリジンおよびピリミジン誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6187777B1 (https=) |
| EP (1) | EP1054887B1 (https=) |
| JP (1) | JP2003502272A (https=) |
| AT (1) | ATE323088T1 (https=) |
| AU (1) | AU747920B2 (https=) |
| CA (1) | CA2319275C (https=) |
| CY (1) | CY1105476T1 (https=) |
| DE (1) | DE69930835T2 (https=) |
| DK (1) | DK1054887T3 (https=) |
| ES (1) | ES2257851T3 (https=) |
| PT (1) | PT1054887E (https=) |
| SI (1) | SI1054887T1 (https=) |
| WO (1) | WO1999040091A1 (https=) |
Families Citing this family (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2264819C (en) * | 1996-09-04 | 2010-03-23 | Intertrust Technologies Corp. | Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing, and rights management |
| DE122007000044I2 (de) * | 1997-01-07 | 2011-05-05 | Amylin Pharmaceuticals Inc | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
| EP1028964A1 (en) | 1997-11-11 | 2000-08-23 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| ATE314371T1 (de) * | 1998-11-10 | 2006-01-15 | Merck & Co Inc | Spiro-indole als y5-rezeptor antagonisten |
| ES2180338T3 (es) | 1998-11-12 | 2003-02-01 | Neurocrine Biosciences Inc | Antagonistas del receptor de crf y metodos relacionados. |
| US6531475B1 (en) | 1998-11-12 | 2003-03-11 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
| SI1165564T1 (sl) * | 1999-04-08 | 2009-08-31 | Ind Res Ltd | Postopek priprave inhibitorjev metabolizma nukleozidov |
| GB9915437D0 (en) | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| JP4815083B2 (ja) * | 1999-08-31 | 2011-11-16 | メルク・シャープ・エンド・ドーム・コーポレイション | 複素環化合物およびそれの使用方法 |
| ES2277855T3 (es) * | 1999-09-30 | 2007-08-01 | Neurogen Corporation | Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas. |
| CA2379585C (en) * | 1999-09-30 | 2006-06-20 | James W. Darrow | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| PL354784A1 (en) | 1999-09-30 | 2004-02-23 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
| US6440960B1 (en) | 2000-05-18 | 2002-08-27 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
| US7276492B2 (en) * | 2000-06-01 | 2007-10-02 | Kevorkian Robert C | Use of ACE inhibitors for treatment of patients suffering from behavioral disorders |
| CA2424622A1 (en) * | 2000-10-03 | 2002-04-11 | Clyde W. Hodge | Use of neuropeptide-y antagonists in treatment of alcoholism |
| US8564661B2 (en) | 2000-10-24 | 2013-10-22 | Objectvideo, Inc. | Video analytic rule detection system and method |
| GB0100620D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical cokpounds V |
| US20050226918A1 (en) * | 2001-08-13 | 2005-10-13 | Macdonald Stuart G | Delivery system for insulin and other therapeutic agents |
| US6770652B2 (en) * | 2001-10-18 | 2004-08-03 | Duquesne University Of The Holy Ghost | Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
| ES2193875B2 (es) | 2002-04-09 | 2005-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. |
| AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| TW200403243A (en) * | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
| EP1927594A1 (en) | 2003-01-14 | 2008-06-04 | Arena Pharmaceuticals, Inc. | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| UA92450C2 (ru) * | 2003-01-14 | 2010-11-10 | Арена Фармасьютикалз, Инк. | 1,2,3-тризамещенные арильные и гетероарильные производные как модуляторы метаболизма, профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия |
| WO2004076413A2 (en) * | 2003-02-24 | 2004-09-10 | Arena Pharmaceuticals, Inc. | Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism |
| CA2517083A1 (en) | 2003-03-04 | 2004-09-16 | Addex Pharmaceuticals Sa | Novel aminopyridine derivatives as mglur5 antagonists |
| WO2004092177A1 (en) | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
| WO2004092173A2 (en) | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | A2a adenosine receptor antagonists |
| WO2004092170A2 (en) | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists |
| US7616233B2 (en) * | 2003-06-26 | 2009-11-10 | Fotonation Vision Limited | Perfecting of digital image capture parameters within acquisition devices using face detection |
| ATE365167T1 (de) * | 2003-07-10 | 2007-07-15 | Neurogen Corp | Aryl-substituierte benzo(d)isothiazol-3-ylamin analoga als capsaicinrezeptormodulatoren |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| ES2222833B1 (es) | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos. |
| ZA200610669B (en) * | 2004-06-02 | 2008-06-25 | Takeda Pharmaceutical | Fused heterocyclic compound |
| CA2569016C (en) * | 2004-06-02 | 2012-11-27 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| PL1756084T3 (pl) * | 2004-06-04 | 2009-06-30 | Arena Pharm Inc | Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie zaburzeń z metabolizmem związanych |
| MX2007000631A (es) * | 2004-07-16 | 2007-03-30 | Sunesis Pharmaceuticals Inc | Tienopirimidinas utiles como inhibidores de aurora cinasa. |
| GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| US7674822B2 (en) | 2004-11-24 | 2010-03-09 | Wyeth | PTP1b inhibitors |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| FR2878849B1 (fr) | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | Indoles substitues, compositions les contenant, procede de fabrication et utilisation |
| DOP2006000010A (es) | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
| MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| BRPI0609802A2 (pt) * | 2005-05-20 | 2017-05-02 | Alantos Pharmaceuticals Holding Inc | composto, composição farmacêutica e uso de um composto |
| US20070155738A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| KR101142363B1 (ko) * | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
| US20100160359A1 (en) * | 2005-09-16 | 2010-06-24 | Arena Pharmaceuticals, Inc. | Modulators of Metabolism and the Treatment of Disorders Related Thereto |
| UY29825A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones |
| UY29823A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones |
| WO2007069565A1 (ja) | 2005-12-12 | 2007-06-21 | Ono Pharmaceutical Co., Ltd. | 二環式複素環化合物 |
| GB0608820D0 (en) | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| TW200811147A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
| TW200811140A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
| JP5140080B2 (ja) | 2006-09-21 | 2013-02-06 | ラクオリア創薬株式会社 | 選択的アシッドポンプ阻害剤としてのベンゾイミダゾール誘導体 |
| MX2009005950A (es) | 2006-12-07 | 2009-10-12 | Genentech Inc | Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso. |
| RU2470936C2 (ru) * | 2006-12-07 | 2012-12-27 | Дженентек, Инк. | Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения |
| WO2008082839A2 (en) * | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| CA2704711C (en) | 2007-09-24 | 2016-07-05 | Genentech, Inc. | Thiazolopyrimidine p13k inhibitor compounds and methods of use |
| JP5348725B2 (ja) * | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| EP2215094B1 (en) | 2007-11-15 | 2016-01-27 | YM BioSciences Australia Pty Ltd | N-containing heterocyclic compounds |
| AR070454A1 (es) * | 2008-02-27 | 2010-04-07 | Nycomed Gmbh | Pirrolopirimidincarboxamidas y composiciones farmaceuticas que las comprenden |
| CA2729045A1 (en) * | 2008-07-31 | 2010-02-04 | Philippe Bergeron | Pyrimidine compounds, compositions and methods of use |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| DE102008052943A1 (de) * | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
| JP5709766B2 (ja) | 2009-03-12 | 2015-04-30 | ジェネンテック， インコーポレイテッド | 造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用 |
| US8158625B2 (en) * | 2009-05-27 | 2012-04-17 | Genentech, Inc. | Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use |
| BRPI1009022A2 (pt) * | 2009-05-27 | 2016-03-08 | Hoffmann La Roche | "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit" |
| US20100331305A1 (en) * | 2009-06-24 | 2010-12-30 | Genentech, Inc. | Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use |
| AR077898A1 (es) * | 2009-08-26 | 2011-09-28 | Nycomed Gmbh | Metilpirrolopirimidincarboxamidas |
| JP5579864B2 (ja) * | 2009-11-12 | 2014-08-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｎ−９−置換プリン化合物、組成物及び使用の方法 |
| EP2499143B1 (en) * | 2009-11-12 | 2016-03-16 | F.Hoffmann-La Roche Ag | N7-substituted purine and pyrazolopyrimidine compounds, compositions and methods of use |
| JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| WO2011130654A1 (en) | 2010-04-16 | 2011-10-20 | Genentech, Inc. | Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy |
| EA201300283A1 (ru) * | 2010-08-27 | 2013-08-30 | Мерк Патент Гмбх | Производные фуропиридина |
| EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140004209A1 (en) | 2010-12-22 | 2014-01-02 | Genentech, Inc. | Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms |
| PT3590928T (pt) | 2011-04-08 | 2021-08-19 | Janssen Sciences Ireland Unlimited Co | Derivados de pirimidina para o tratamento de infeções virais |
| HRP20181667T1 (hr) | 2011-07-22 | 2018-12-14 | Glaxosmithkline Llc | Pripravak |
| DE102011111400A1 (de) * | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
| JP6349256B2 (ja) | 2011-11-09 | 2018-06-27 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染の治療のためのプリン誘導体 |
| WO2013078126A1 (en) | 2011-11-23 | 2013-05-30 | Cancer Research Technology Limited | Thienopyrimidine inhibitors of atypical protein kinase c |
| US9045493B2 (en) * | 2012-02-09 | 2015-06-02 | Merck Patent Gmbh | Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives |
| CA2863717C (en) * | 2012-02-21 | 2021-09-28 | Lars Burgdorf | Furopyridine derivatives |
| TW201414734A (zh) | 2012-07-10 | 2014-04-16 | Takeda Pharmaceutical | 氮雜吲哚衍生物 |
| EA035790B1 (ru) | 2012-07-13 | 2020-08-11 | Янссен Сайенсиз Айрлэнд Юси | Макроциклические пурины для лечения вирусных инфекций |
| EA026354B1 (ru) | 2012-08-24 | 2017-03-31 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Пиразолопиримидиновые соединения |
| DK2906563T3 (en) | 2012-10-10 | 2018-06-06 | Janssen Sciences Ireland Uc | PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES |
| EA035431B1 (ru) | 2012-11-16 | 2020-06-15 | Янссен Сайенсиз Айрлэнд Юси | Гетероциклические замещенные производные 2-амино-хиназолина в качестве модуляторов tlr7 и/или tlr8 для лечения вирусных инфекций |
| AU2013348217B2 (en) | 2012-11-20 | 2016-10-06 | Glaxosmithkline Llc | Novel compounds |
| EA028480B1 (ru) | 2012-11-20 | 2017-11-30 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Новые соединения |
| BR112015011439A2 (pt) | 2012-11-20 | 2017-07-11 | Glaxosmithkline Llc | composto, composição farmacêutica, composição de vacina, e, uso de um composto |
| WO2014100071A2 (en) * | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted pyrrolopyrimidines as hdm2 inhibitors |
| SG11201506639XA (en) | 2013-02-21 | 2015-09-29 | Janssen Sciences Ireland Uc | 2-aminopyrimidine derivatives for the treatment of viral infections |
| EP2959014B1 (en) | 2013-02-25 | 2019-11-13 | Genentech, Inc. | Methods and compositions for detecting and treating drug resistant akt mutant |
| CN110590809B (zh) | 2013-03-29 | 2022-04-19 | 爱尔兰詹森科学公司 | 用于治疗病毒感染的大环脱氮-嘌呤酮 |
| SG11201509520QA (en) | 2013-05-24 | 2015-12-30 | Janssen Sciences Ireland Uc | Pyridone derivatives for the treatment of viral infections and further diseases |
| PT3030563T (pt) * | 2013-06-27 | 2017-11-15 | Janssen Sciences Ireland Uc | Derivados de pirrolo[3,2-d]pirimidina para o tratamento de infeções virais e outras doenças |
| DK3027624T3 (en) | 2013-07-30 | 2019-01-07 | Janssen Sciences Ireland Uc | THIENO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS |
| WO2015106012A1 (en) | 2014-01-09 | 2015-07-16 | Takeda Pharmaceutical Company Limited | Azaindole derivatives |
| CZ305472B6 (cs) * | 2014-04-30 | 2015-10-14 | Masarykova Univerzita | Substituované furo[3,2-b]pyridiny pro použití jako léčiva |
| EP2940022B1 (en) * | 2014-04-30 | 2020-09-02 | Masarykova Univerzita | Furopyridines as inhibitors of protein kinases |
| GB201411236D0 (en) * | 2014-06-25 | 2014-08-06 | Takeda Pharmaceutical | Novel compounds |
| CN107454899B (zh) | 2014-10-27 | 2020-05-29 | 大学健康网络 | Ripk2抑制剂及用其治疗癌症的方法 |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| BR112017019736A2 (pt) | 2015-03-15 | 2018-05-22 | Sachem Inc | método de preparação de um material cristalino que compreende óxidos de silício e de alumínio |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| SG11201804901WA (en) | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| MA45539A (fr) | 2016-07-01 | 2019-05-08 | Janssen Sciences Ireland Unlimited Co | Dihydropyranopyrimidines pour le traitement d'infections virales |
| ES2912945T3 (es) | 2016-09-29 | 2022-05-30 | Janssen Sciences Ireland Unlimited Co | Profármacos de pirimidina para el tratamiento de infecciones virales y otras enfermedades |
| MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
| EA201992780A1 (ru) | 2017-06-21 | 2020-06-02 | ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи | Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| CN111448190B (zh) | 2017-11-14 | 2023-09-26 | 百时美施贵宝公司 | 取代的吲哚化合物 |
| BR112020011668A2 (pt) | 2017-12-15 | 2020-11-17 | Bristol-Myers Squibb Company | compostos de éter de indol substituído |
| WO2019126082A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | 6-azaindole compounds |
| JP7313354B2 (ja) | 2017-12-19 | 2023-07-24 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｌｒ阻害剤として有用なアミド置換されたインドール化合物 |
| BR112020012084A2 (pt) | 2017-12-19 | 2020-11-24 | Bristol-Myers Squibb Company | compostos de indol substituído úteis como inibidores de tlr |
| BR112020011984A2 (pt) | 2017-12-20 | 2020-11-17 | Bristol-Myers Squibb Company | compostos de amino indol úteis como inibidores de tlr |
| CA3085942A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
| US11299501B2 (en) * | 2017-12-20 | 2022-04-12 | Bristol-Myers Squibb Company | Diazaindole compounds |
| TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | ２，４－二胺基喹唑啉衍生物及其醫學用途 |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| ES2963696T3 (es) | 2018-10-24 | 2024-04-01 | Bristol Myers Squibb Co | Compuestos diméricos de indol sustituidos |
| CN112955450A (zh) | 2018-10-24 | 2021-06-11 | 百时美施贵宝公司 | 经取代的吲哚和吲唑化合物 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020118183A1 (en) * | 2018-12-06 | 2020-06-11 | Kapoor Tarun M | 2,4-diaminopyrimidine bicycles for treating cancer |
| US12391705B2 (en) | 2018-12-19 | 2025-08-19 | Shy Therapeutics, Llc | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| EP3965888B1 (en) | 2019-05-09 | 2024-08-21 | Bristol-Myers Squibb Company | Substituted benzimidazolone compounds |
| WO2021067326A1 (en) | 2019-10-01 | 2021-04-08 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| CN114829350B (zh) | 2019-10-04 | 2024-05-28 | 百时美施贵宝公司 | 经取代的咔唑化合物 |
| CN114829362A (zh) * | 2019-12-10 | 2022-07-29 | 成都倍特药业股份有限公司 | 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物 |
| TW202214106A (zh) * | 2020-08-14 | 2022-04-16 | 瑞士商先正達農作物保護公司 | 化學方法 |
| WO2024017227A1 (zh) * | 2022-07-21 | 2024-01-25 | 长春金赛药业有限责任公司 | 取代的稠环大麻素受体化合物及其应用 |
| WO2026067383A1 (zh) * | 2024-09-27 | 2026-04-02 | 上海轻胜谦远生物科技有限公司 | 咪唑并吡啶衍生物及其用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA907618A (en) | 1972-08-15 | Woitun Eberhard | 2-aminoalkylamino-thieno(3,2-d)pyrimidines and process for their production | |
| BE754606A (fr) | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
| US3883651A (en) | 1969-08-08 | 1975-05-13 | Boehringer Sohn Ingelheim | Pharmaceutical compositions containing a 2-(aminoalkylamino)-4-amino-thieno{8 3,2-d{9 pyrimidine and method of use |
| BE759493A (fr) | 1969-11-26 | 1971-05-25 | Thomae Gmbh Dr K | Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer |
| US3763156A (en) | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
| RO62428A (fr) | 1971-05-04 | 1978-01-15 | Thomae Gmbh Dr K | Procede pour la preparation des thyeno-(3,2-d)-pyrimidines |
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US4731368A (en) | 1986-12-08 | 1988-03-15 | Merck & Co., Inc. | Thienopyridine sulfonamides and their ophthalmological formulation |
| US4808595A (en) | 1986-12-24 | 1989-02-28 | Merck & Co., Inc. | Furopyridine sulfonamides and their opthalmological compositions |
| JPH0527391A (ja) | 1991-07-23 | 1993-02-05 | Konica Corp | 新規な写真用カプラー |
| FR2687402B1 (fr) | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
| KR19990067704A (ko) | 1992-12-17 | 1999-08-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물 |
| WO1995010506A1 (en) | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| US5461065A (en) | 1993-10-15 | 1995-10-24 | Eli Lilly And Company | Methods for inhibiting endometriosis |
| US5441965A (en) | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting thrombin |
| US5439923A (en) | 1993-12-21 | 1995-08-08 | Eli Lilly And Company | Method of inhibiting seborrhea and acne |
| DE59500788D1 (de) | 1994-05-03 | 1997-11-20 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
| TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| JPH10510510A (ja) | 1994-06-09 | 1998-10-13 | スミスクライン・ビーチャム・コーポレイション | エンドセリン受容体拮抗物質 |
| DK0765327T3 (da) | 1994-06-16 | 1999-11-29 | Pfizer | Pyrazolo- og pyrrolopyridiner |
| EP0895781A3 (en) | 1994-10-20 | 1999-07-07 | Eli Lilly And Company | Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins |
| US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| AU692977B2 (en) | 1994-11-07 | 1998-06-18 | Pfizer Inc. | Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands |
| EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases |
| EP0770080B1 (en) | 1995-05-12 | 1999-07-14 | Neurogen Corporation | Novel deazapurine derivatives; a new class of crf1 specific ligands |
| US5644057A (en) * | 1995-05-12 | 1997-07-01 | Neurogen Corporation | Deazapurine derivatives; a new class of CRF1 specific ligands |
| JP3290666B2 (ja) | 1995-06-07 | 2002-06-10 | ファイザー・インコーポレーテッド | 複素環式の縮合環ピリミジン誘導体 |
| FR2735777B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
| AU7692996A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Receptor antagonists |
| AU7626496A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Heteroaryl compounds |
| AU7692696A (en) | 1995-12-01 | 1997-06-27 | Novartis Ag | Heteroaryl derivatives |
| WO1997020822A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
| PT778277E (pt) | 1995-12-08 | 2003-11-28 | Pfizer | Derivados heterociclicos substituidos como antagonistas do crf |
| EP0871442A1 (en) | 1996-01-09 | 1998-10-21 | Eli Lilly And Company | Benzimidzolyl neuropeptide y receptor antagonists |
| US6255310B1 (en) | 1996-02-07 | 2001-07-03 | Neurocrine Biosciences Inc. | Thiophenopyrimidines |
| US5688796A (en) | 1996-03-12 | 1997-11-18 | Eli Lilly And Company | Heterocyclic substituted benzothiophenes, compositions, and methods |
| US6011039A (en) | 1996-03-21 | 2000-01-04 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives |
| AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
| BR9710808A (pt) | 1996-08-06 | 1999-08-17 | Pfizer | Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos |
| WO1998006703A1 (en) | 1996-08-14 | 1998-02-19 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
| WO1998007726A1 (en) | 1996-08-23 | 1998-02-26 | Novartis Ag | Substituted pyrrolopyrimidines and processes for their preparation |
| TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
| JP3621706B2 (ja) | 1996-08-28 | 2005-02-16 | ファイザー・インク | 置換された６，５―ヘテロ―二環式誘導体 |
| WO1998035957A1 (en) | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
| AU6267198A (en) | 1997-02-14 | 1998-09-08 | Bayer Corporation | Amides as npy5 receptor antagonists |
| CN1264381A (zh) | 1997-08-05 | 2000-08-23 | 辉瑞产品公司 | 4－氨基吡咯并(3,2－d)嘧啶作为神经肽Y受体拮抗药 |
-
1999
- 1999-02-04 US US09/246,775 patent/US6187777B1/en not_active Expired - Fee Related
- 1999-02-05 AT AT99906756T patent/ATE323088T1/de not_active IP Right Cessation
- 1999-02-05 AU AU26590/99A patent/AU747920B2/en not_active Ceased
- 1999-02-05 ES ES99906756T patent/ES2257851T3/es not_active Expired - Lifetime
- 1999-02-05 EP EP99906756A patent/EP1054887B1/en not_active Expired - Lifetime
- 1999-02-05 WO PCT/US1999/002500 patent/WO1999040091A1/en not_active Ceased
- 1999-02-05 SI SI9930893T patent/SI1054887T1/sl unknown
- 1999-02-05 DE DE69930835T patent/DE69930835T2/de not_active Expired - Lifetime
- 1999-02-05 DK DK99906756T patent/DK1054887T3/da active
- 1999-02-05 CA CA002319275A patent/CA2319275C/en not_active Expired - Fee Related
- 1999-02-05 PT PT99906756T patent/PT1054887E/pt unknown
- 1999-02-05 JP JP2000530520A patent/JP2003502272A/ja not_active Withdrawn
-
2000
- 2000-08-16 US US09/640,263 patent/US6583154B1/en not_active Expired - Fee Related
-
2006
- 2006-07-06 CY CY20061100932T patent/CY1105476T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003502272A5 (https=) | ||
| TWI695002B (zh) | 用於治療發炎病症之新穎化合物及彼等之醫藥組合物 | |
| US20080153811A1 (en) | Methods of Treating Cognitive Impairment and Dementia | |
| EP1027050B1 (en) | 1,3-thiazoles as adenosine a3 receptor antagonists for the treatment of allergy, asthma and diabetes | |
| JP2020531498A5 (https=) | ||
| JP4862654B2 (ja) | 芳香環縮合ピリミジン誘導体 | |
| US20060258691A1 (en) | Methods and compositions for improving cognition | |
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| RU2205827C2 (ru) | Производное ацилпиперазинилпиримидина, способы его получения, фармацевтическая композиция | |
| RU2016102137A (ru) | Первичные карбоксамиды в качестве ингибиторов bik | |
| US20100081691A1 (en) | Multicyclic compounds and methods of their use | |
| RU2004126945A (ru) | Производные дигидробензодиазепин-2-она для лечения неврологических нарушений | |
| US10072003B2 (en) | Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use | |
| JP2005538134A5 (https=) | ||
| JP2015510938A5 (https=) | ||
| JP2008513514A5 (https=) | ||
| JP2019535728A (ja) | キナーゼ阻害剤としての複素環式アミド | |
| JP2007519753A5 (https=) | ||
| JP2016523911A5 (https=) | ||
| JP2007510689A5 (https=) | ||
| NZ604004A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| RU2009120389A (ru) | Гетероциклические соединения в качестве противовоспалительных агентов | |
| JP2012522748A5 (https=) | ||
| JP2006508935A5 (https=) | ||
| JP2018524338A5 (https=) |